Masitinib (AB1010)Tyrosine kinase inhibitor, potent and selective CAS# 790299-79-5 |
2D Structure
- ML314
Catalog No.:BCC4154
CAS No.:1448895-09-7
- Aprepitant
Catalog No.:BCC1101
CAS No.:170729-80-3
- Fosaprepitant
Catalog No.:BCC4281
CAS No.:172673-20-0
- NKP608
Catalog No.:BCC1802
CAS No.:177707-12-9
- Fosaprepitant dimeglumine salt
Catalog No.:BCC4954
CAS No.:265121-04-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 790299-79-5 | SDF | Download SDF |
PubChem ID | 10074640 | Appearance | Powder |
Formula | C28H30N6OS | M.Wt | 498.64 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | AB1010 | ||
Solubility | DMSO : ≥ 100 mg/mL (200.55 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide | ||
SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5 | ||
Standard InChIKey | WJEOLQLKVOPQFV-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Masitinib is a potent and selective inhibitor of tyrosine kinases with IC50 values of 200 nM, 540 nM and 800 nM for KIT, PDGFRα and PDGFRβ, respectively. | |||||
Targets | KIT | PDGFRα | PDGFRβ | |||
IC50 | 200 nM | 540 nM | 800 nM |
Masitinib (AB1010) Dilution Calculator
Masitinib (AB1010) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0055 mL | 10.0273 mL | 20.0545 mL | 40.1091 mL | 50.1364 mL |
5 mM | 0.4011 mL | 2.0055 mL | 4.0109 mL | 8.0218 mL | 10.0273 mL |
10 mM | 0.2005 mL | 1.0027 mL | 2.0055 mL | 4.0109 mL | 5.0136 mL |
50 mM | 0.0401 mL | 0.2005 mL | 0.4011 mL | 0.8022 mL | 1.0027 mL |
100 mM | 0.0201 mL | 0.1003 mL | 0.2005 mL | 0.4011 mL | 0.5014 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
The stem cell factor receptor (KIT) is a therapeutic target for the cancer, mastocytosis, and inflammatory diseases treatment. Masitinib (AB1010) is a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT.
In vitro: Masitinib potently inhibited the intracellular kinase Lyn and recombinant PDGFR as well as fibroblast growth factor receptor 3. Moreover, masitinib showed weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases. These findings suggest that Masitinib (AB1010) will exhibit a better safety profile than other tyrosine kinase inhibitors; in fact, masitinib-induced genotoxicity or cardiotoxicity has not been observed in animal so far [1].
In vivo: In vivo, masitinib blocked tumour growth in mice with subcutaneous grafts of Ba/F3 cells expressing a juxtamembrane KIT mutant. We found that tumour growth was blocked following 5 days of treatment with masitinib. After withdrawal of masitinib treatment after day 5, tumour growth was once again evident [1].
Clinical trial: A Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Thirty patients were enrolled with a median follow-up of 34 months. Masitinib appears to be effective as a first-line treatment of advanced GIST with comparable results to imatinib in terms of safety and response. PFS and OS results data show promise that masitinib may provide sustainable benefits [2].
Reference:
[1] Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4(9):e7258.
[2] Sylvie Bonvalot , Alain Moussy , Jean-Pierre Kinet , et al. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). European Journal of Cancer. 2010(46): 1344-1351
- Eurycomalin A
Catalog No.:BCN3654
CAS No.:790234-20-7
- 4'-O-Methylnyasol
Catalog No.:BCN7564
CAS No.:79004-25-4
- Camphene
Catalog No.:BCC9217
CAS No.:79-92-5
- Retinyl (Vitamin A) Palmitate
Catalog No.:BCC4749
CAS No.:79-81-2
- Lanosterol
Catalog No.:BCN3332
CAS No.:79-63-0
- Oxytetracycline (Terramycin)
Catalog No.:BCC4819
CAS No.:79-57-2
- Methacrylamide
Catalog No.:BCN8157
CAS No.:79-39-0
- Guan-fu base G
Catalog No.:BCN8493
CAS No.:78969-72-9
- DL-AP7
Catalog No.:BCC6551
CAS No.:78966-69-5
- L-AP6
Catalog No.:BCC6612
CAS No.:78944-89-5
- Chicanine
Catalog No.:BCN7818
CAS No.:78919-28-5
- Iloprost
Catalog No.:BCC7247
CAS No.:78919-13-8
- SNAP
Catalog No.:BCC6712
CAS No.:79032-48-7
- β-Estradiol - d3
Catalog No.:BCC5365
CAS No.:79037-37-9
- L-AP5
Catalog No.:BCC6554
CAS No.:79055-67-7
- D-AP5
Catalog No.:BCC6553
CAS No.:79055-68-8
- Boc-Alaninol
Catalog No.:BCC2730
CAS No.:79069-13-9
- Boc-Valinol
Catalog No.:BCC2695
CAS No.:79069-14-0
- Boc-Serinol(Bzl)
Catalog No.:BCC2706
CAS No.:79069-15-1
- (-)-Corlumine
Catalog No.:BCN6632
CAS No.:79082-64-7
- Polygalasaponin XXXI
Catalog No.:BCN2857
CAS No.:79103-90-5
- Lariciresinol acetate
Catalog No.:BCN4577
CAS No.:79114-77-5
- Hannokinol
Catalog No.:BCN6514
CAS No.:79120-40-4
- A-7 hydrochloride
Catalog No.:BCC6625
CAS No.:79127-24-5
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.[Pubmed:19789626]
PLoS One. 2009 Sep 30;4(9):e7258.
BACKGROUND: The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of Masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT. METHODOLOGY/PRINCIPAL FINDINGS: In vitro, masitinib had greater activity and selectivity against KIT than imatinib, inhibiting recombinant human wild-type KIT with an half inhibitory concentration (IC(50)) of 200+/-40 nM and blocking stem cell factor-induced proliferation and KIT tyrosine phosphorylation with an IC(50) of 150+/-80 nM in Ba/F3 cells expressing human or mouse wild-type KIT. Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases. This highly selective nature of masitinib suggests that it will exhibit a better safety profile than other tyrosine kinase inhibitors; indeed, masitinib-induced cardiotoxicity or genotoxicity has not been observed in animal studies. Molecular modelling and kinetic analysis suggest a different mode of binding than imatinib, and masitinib more strongly inhibited degranulation, cytokine production, and bone marrow mast cell migration than imatinib. Furthermore, masitinib potently inhibited human and murine KIT with activating mutations in the juxtamembrane domain. In vivo, masitinib blocked tumour growth in mice with subcutaneous grafts of Ba/F3 cells expressing a juxtamembrane KIT mutant. CONCLUSIONS: Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity.
Masitinib (AB1010), from canine tumor model to human clinical development: where we are?[Pubmed:24405856]
Crit Rev Oncol Hematol. 2014 Jul;91(1):98-111.
Masitinib mesylate (AB1010) is a novel potent and selective tyrosine kinase inhibitor, targeting mainly wild-type and mutated c-Kit receptor (c-KitR), Platelet Derived Growth Factor Receptor-alfa/beta (PDGFRa/ss), Lymphocyte-specific kinase (Lck), Lck/Yes-related protein (LYn), Fibroblast Growth Factor Receptor 3 (FGFR3) and Focal Adhesion Kinase (FAK). It is the first anticancer therapy approved in veterinary medicine for the treatment of unresectable canine mast cell tumors (CMCTs), harboring activating c-KitR mutations, at dose of 12.5mg/kg once daily. Considering its anti-proliferative action, principally given by inhibiting the MCs c-KitR anti-angiogenic pathway that leads cancer progression, and its role as chemosensitizer, masitinib is under clinical investigation in several human malignancies (Gastro-Intestinal Stromal Tumors, acute myeloid leukemia, systemic mastocytosis, pancreatic cancer, multiple myeloma, non-small cell lung cancer, melanoma, ovarian and prostate cancer), which are characterized by similar canine c-KIT proto-oncogene mutations. Here, we analyze masitinib structure activity, its pharmacokinetics compared to imatinib, the c-KitR pathway referring to the most frequent c-KIT mutations sensitive or resistant to this novel drug compared to imatinib, and masitinib safety profile. We, also, explore preclinical and clinical (completed and ongoing) trials with the aim to emphasize as this recent anti-angiogenic therapy, at first approved in CMCTs and, currently in development for the treatment of several human neoplasms, could be represent a milestone in translational oncology, in which the murine experimental model of cancer research could be integrated by canine spontaneous tumor model.